<DOC>
	<DOCNO>NCT01147523</DOCNO>
	<brief_summary>The primary aim study effect spironolactone vitamin E versus vitamin E serum level adipokines 52 week post-treatment .</brief_summary>
	<brief_title>Effect Spironolactone Vitamin E Patients With Nonalcoholic Fatty Liver Disease</brief_title>
	<detailed_description>Unlike chronic liver disease ( e.g. , hepatitis C ) , effective treatment strategy NAFLD . Currently , management NAFLD include modification underlie risk factor , detection patient progressed cirrhosis , management cirrhosis-related morbidity transplantation patient end-stage liver disease . Diet , exercise , bariatric surgery pharmacologic treatment , include weight loss agent , insulin sensitizer , lipid-lowering agent , ursodeoxycholic acid vitamin E investigate promising result . The renin-angiotensin-aldosterone system ( RAAS ) implicate pathogenesis insulin resistance ( IR ) nonalcoholic fatty liver disease ( NAFLD ) . Recently , low-dose ( 25-50 mg/day ) aldosterone antagonists patient heart failure diminish mortality , possibly reduce cardiac vascular fibrosis . Moreover , beneficial effect spironolactone mouse model diet-induced diabetes NAFLD report . However , knowledge , role spironolactone NAFLD patient investigate yet . The primary aim study effect spironolactone vitamin E versus vitamin E serum level adipokines 52 week post-treatment .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Bright liver ultrasound image increase liver function test least 6 month liver biopsy Biopsyproven NAFLD ( either NAFL NASH ) accord NAFLD Activity Score ( NAS ) Ethanol consumption 20 g/day Known intolerance spironolactone vitamin E History liver disease ( chronic viral hepatitis , autoimmune hepatitis , druginduced liver disease , primary biliary cirrhosis , hemochromatosis , Wilson 's disease Î±1antitrypsin deficiency ) Previous exposure hepatotoxic drug Spironolactone vitamin E administration within one year screen Type I Diabetes Mellitus Pancreatitis Uncontrolled hypothyroidism hyperthyroidism Adrenal Insufficiency Renal Failure Cancer Pregnancy Exclusion criterion generally propose PIVENS trial design two modification : ) know intolerance spironolactone exclusion criterion b ) inclusion patient T2DM receive thiazolidinediones insulin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>nonalcoholic fatty liver disease</keyword>
	<keyword>nonalcoholic steatohepatitis</keyword>
	<keyword>adipokines</keyword>
	<keyword>spironolactone</keyword>
	<keyword>vitamin E</keyword>
	<keyword>adiponectin</keyword>
	<keyword>visfatin</keyword>
	<keyword>leptin</keyword>
	<keyword>resistin</keyword>
	<keyword>TNF-alpha</keyword>
	<keyword>IL-6</keyword>
	<keyword>IL-1</keyword>
</DOC>